-
Something wrong with this record ?
Lung cancer biomarker testing: perspective from Europe
E. Thunnissen, B. Weynand, D. Udovicic-Gagula, L. Brcic, M. Szolkowska, P. Hofman, S. Smojver-Ježek, S. Anttila, F. Calabrese, I. Kern, B. Skov, S. Perner, VG. Dale, Z. Eri, A. Haragan, D. Leonte, L. Carvallo, SS. Prince, S. Nicholson, I....
Language English Country China
Document type Journal Article, Review
NLK
Free Medical Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
- Publication type
- Journal Article MeSH
- Review MeSH
A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Department of Cardiac Thoracic Vascular Sciences and Public Health University of Padova Padova Italy
Department of Histopathology St James's Hospital Dublin 8 Ireland
Department of Pathology AmsterdamUMC Location VU Medical Center Amsterdam The Netherlands
Department of Pathology HUSLAB Helsinki and Uusimaa Health Care District Helsinki Finland
Department of Pathology Royal Liverpool University Hospital Liverpool England
Department of Pathology St Olavs Hospital Trondheim Norway
Department of Pathology University Hospital Copenhagen Ø Denmark
Diagnostic and Research Institute of Pathology Medical University of Graz Graz Austria
Laboratory for cytology and pathology University Clinic Golnik Golnik Slovenia
National Institute of Pneumology Pathology Department Bucharest Romania
National Tuberculosis and Lung Diseases Research Institute Department of Pathology Warsaw Poland
Nice University Hospital FHU OncoAge Laboratory of Clinical and Experimental Pathology Nice France
Pathology Department Herestraat Leuven Belgium
Pathology Department Passeig de la Vall d'Hebron 119 129 Barcelona Spain
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20022113
- 003
- CZ-PrNML
- 005
- 20201204093809.0
- 007
- ta
- 008
- 201125s2020 cc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21037/tlcr.2020.04.07 $2 doi
- 035 __
- $a (PubMed)32676354
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a cc
- 100 1_
- $a Thunnissen, Erik $u Department of Pathology, AmsterdamUMC, Location VU Medical Center, Amsterdam, The Netherlands.
- 245 10
- $a Lung cancer biomarker testing: perspective from Europe / $c E. Thunnissen, B. Weynand, D. Udovicic-Gagula, L. Brcic, M. Szolkowska, P. Hofman, S. Smojver-Ježek, S. Anttila, F. Calabrese, I. Kern, B. Skov, S. Perner, VG. Dale, Z. Eri, A. Haragan, D. Leonte, L. Carvallo, SS. Prince, S. Nicholson, I. Sansano, A. Ryska,
- 520 9_
- $a A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Weynand, Birgit $u Pathology Department, Herestraat, Leuven, Belgium.
- 700 1_
- $a Udovicic-Gagula, Dalma $u Clinical Center University of Sarajevo, Department of Pathology and Cytology, Sarajevo, Bosnia and Herzegovina.
- 700 1_
- $a Brcic, Luka $u Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Szolkowska, Malgorzata $u National Tuberculosis and Lung Diseases Research Institute, Department of Pathology, Warsaw, Poland.
- 700 1_
- $a Hofman, Paul $u Nice University Hospital, FHU OncoAge, Laboratory of Clinical and Experimental Pathology, Nice, France.
- 700 1_
- $a Smojver-Ježek, Silvana $u Clinical Unit for Pulmonary Cytology, Department of Pathology and Cytology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
- 700 1_
- $a Anttila, Sisko $u Department of Pathology, HUSLAB, Helsinki and Uusimaa Health Care District, Helsinki, Finland.
- 700 1_
- $a Calabrese, Fiorella $u Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
- 700 1_
- $a Kern, Izidor $u Laboratory for cytology and pathology, University Clinic Golnik, Golnik, Slovenia.
- 700 1_
- $a Skov, Birgit $u Department of Pathology, University Hospital, Copenhagen Ø, Denmark.
- 700 1_
- $a Perner, Sven $u Institute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. Pathology, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
- 700 1_
- $a Dale, Vibeke G $u Department of Pathology, St. Olavs Hospital, Trondheim, Norway.
- 700 1_
- $a Eri, Zivka $u Institute for pulmonary diseases of Vojvodina, Department for Pathology, put dr Goldmana 4, Sremska Kamenica, Serbia.
- 700 1_
- $a Haragan, Alex $u Department of Pathology, Royal Liverpool University Hospital, Liverpool, England.
- 700 1_
- $a Leonte, Diana $u National Institute of Pneumology, Pathology Department, Bucharest, Romania.
- 700 1_
- $a Carvallo, Lina $u Institute of Anatomical and Molecular Pathology, Faculty of Medicine - University of Coimbra, Coimbra, Portugal.
- 700 1_
- $a Prince, Spasenja Savic $u Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
- 700 1_
- $a Nicholson, Siobhan $u Department of Histopathology, St. James's Hospital, Dublin 8, Ireland.
- 700 1_
- $a Sansano, Irene $u Pathology Department, Passeig de la Vall d'Hebron 119-129, Barcelona, Spain.
- 700 1_
- $a Ryska, Ales $u The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital, Hradec Kralove, Czech Republic.
- 773 0_
- $w MED00186389 $t Translational lung cancer research $x 2218-6751 $g Roč. 9, č. 3 (2020), s. 887-897
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32676354 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201204093806 $b ABA008
- 999 __
- $a ind $b bmc $g 1591820 $s 1112785
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 9 $c 3 $d 887-897 $e - $i 2218-6751 $m Translational lung cancer research $n Transl Lung Cancer Res $x MED00186389
- LZP __
- $a Pubmed-20201125
